Analysis of the controversial health care reform plan of French Prime Minister Alain Juppe (Marketletters passim) has underlined divergent interests in the pharmaceutical industry because the financial levy on some companies will be far greater than on others.
One French drug sector source said last week that "the plan will be a bitter pill for everybody - but for some companies it will be impossible to swallow."
The industry remains divided over how the levy will be shared. The drug wholesaler companies already pay a provisional levy, which was introduced in 1991, and will pay an estimated 900 million French francs ($183.5 million) this year, bringing the total levy on the French drug sector to almost 3.5 billion francs ($713.7 million).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze